前立腺全摘除術に対する貯血式自己血輸血における遺伝子組換えヒトエリスロポエチンの効果

Abstract

前立腺全摘除術を施行した18症例を対象とした.1)全例予定量の800mlの貯血が可能であり, 副作用は認めなかった. 2)貧血からの回復も良好で, Hb低下量, 術前Hb増加量及びARRの有効率はそれぞれ72.2%, 72.2%, 66.7%であった. 3)18例中16例(88.9%)は自己血以外の同種血輸血は必要としなかった

The usefulness of recombinant human erythropoietin (rHuEPO) on autologous blood transfusion was investigated in 18 patients undergoing radical prostatectomy (mean age 67.4 years). A total of 800 ml blood was deposited by two donations of 400 ml each, concomitant with subcutaneous administration of 24, 000 U rHuEPO at each donation. All patients completed two successive donations with no adverse effects. The mean hemoglobin concentration was 13.7 g/dl before the donation and 13.0 g/dl on the day of operation. The decrease in hemoglobin was effectively prevented in 12 patients (66.7%) with rHuEPO, when compared with the predicted decrease in the absence of recovery from anemia. During radical prostatectomy, no homologous blood transfusion was required in 16 of 18 patients (88.9%). In conclusion, predeposit autologous blood transfusion with rHuEPO is useful for diminishing the risks associated with homologous blood transfusions.